Eva Kassi

6.5k total citations · 4 hit papers
161 papers, 4.6k citations indexed

About

Eva Kassi is a scholar working on Endocrinology, Diabetes and Metabolism, Epidemiology and Molecular Biology. According to data from OpenAlex, Eva Kassi has authored 161 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Endocrinology, Diabetes and Metabolism, 45 papers in Epidemiology and 30 papers in Molecular Biology. Recurrent topics in Eva Kassi's work include Liver Disease Diagnosis and Treatment (23 papers), Estrogen and related hormone effects (16 papers) and Adrenal and Paraganglionic Tumors (15 papers). Eva Kassi is often cited by papers focused on Liver Disease Diagnosis and Treatment (23 papers), Estrogen and related hormone effects (16 papers) and Adrenal and Paraganglionic Tumors (15 papers). Eva Kassi collaborates with scholars based in Greece, United Kingdom and United States. Eva Kassi's co-authors include Gregory Kaltsas, George P. Chrousos, Panagiota Pervanidou, Paraskevi Moutsatsou, Athanasios G. Papavassiliou, Narjes Nasiri‐Ansari, Harpal Randeva, Zoi Papoutsi, Ioannis Kyrou and Anna Angelousi and has published in prestigious journals such as Circulation, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Eva Kassi

148 papers receiving 4.5k citations

Hit Papers

Metabolic syndrome: definitions and controversies 2011 2026 2016 2021 2011 2021 2022 2024 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Metabolic syndrome: definitions and controversies
    2011 1.1k citations Eva Kassi, Gregory Kaltsas et al. profile →
  2. Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis
    2021 234 citations Narjes Nasiri‐Ansari, Ioannis Kyrou et al. International Journal of Molecular Sciences profile →
  3. SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
    2022 108 citations Θεόδωρος Ανδρουτσάκος, Narjes Nasiri‐Ansari et al. International Journal of Molecular Sciences profile →
  4. Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD
    2024 53 citations Chris Kite, Kamaljit Chatha et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eva Kassi Greece 33 1.2k 1.1k 1.1k 587 583 161 4.6k
Choon Hee Chung South Korea 39 1.3k 1.1× 1.4k 1.3× 914 0.8× 638 1.1× 560 1.0× 178 4.4k
Sidney Tam China 38 1.1k 0.9× 1.3k 1.2× 1.2k 1.1× 827 1.4× 724 1.2× 118 4.8k
Naoto Nakamura Japan 38 1.3k 1.1× 966 0.9× 1.1k 1.0× 896 1.5× 1.1k 1.9× 193 5.3k
Bogusław Okopień Poland 35 2.2k 1.8× 1.4k 1.3× 797 0.7× 577 1.0× 1.2k 2.1× 398 5.1k
Giovanni Tarantino Italy 43 1.2k 1.0× 881 0.8× 2.7k 2.5× 774 1.3× 614 1.1× 148 4.9k
Massimo Collino Italy 43 715 0.6× 2.0k 1.9× 882 0.8× 926 1.6× 537 0.9× 141 5.1k
Carla Lubrano Italy 34 872 0.7× 648 0.6× 612 0.6× 1.4k 2.4× 432 0.7× 126 3.9k
Guang Ning China 33 757 0.6× 1.4k 1.3× 1.1k 1.0× 993 1.7× 410 0.7× 112 4.4k
Goji Hasegawa Japan 39 1.2k 1.0× 1.1k 1.0× 869 0.8× 991 1.7× 1.1k 1.8× 190 5.5k
Carlo Sabbà Italy 46 693 0.6× 1.5k 1.3× 1.3k 1.2× 846 1.4× 1.7k 2.9× 211 6.7k

Countries citing papers authored by Eva Kassi

Since Specialization
Citations

This map shows the geographic impact of Eva Kassi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Kassi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Kassi more than expected).

Fields of papers citing papers by Eva Kassi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Kassi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Kassi. The network helps show where Eva Kassi may publish in the future.

Co-authorship network of co-authors of Eva Kassi

This figure shows the co-authorship network connecting the top 25 collaborators of Eva Kassi. A scholar is included among the top collaborators of Eva Kassi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Kassi. Eva Kassi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Papadakos, Stavros P., et al.. (2025). Animal models of lean metabolic dysfunction-associated steatotic liver disease (MASLD): bridging pathogenesis and novel drug discovery. Expert Opinion on Drug Discovery. 20(12). 1683–1700.
2.
Kite, Chris, Kamaljit Chatha, Nwe Ni Than, et al.. (2025). Cardiovascular Disease in the Context of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Comprehensive Narrative Review. International Journal of Molecular Sciences. 26(23). 11275–11275.
3.
Kite, Chris, et al.. (2025). Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Emerging Pathogenic Mechanisms and Therapeutic Implications. SHILAP Revista de lepidopterología. 5(1). 11–11. 7 indexed citations
4.
Chrousos, George P., et al.. (2024). Stress-Related Roles of Exosomes and Exosomal miRNAs in Common Neuropsychiatric Disorders. International Journal of Molecular Sciences. 25(15). 8256–8256. 6 indexed citations
5.
Goliopoulou, Athina, Panagiotis Theofilis, Evangelos Oikonomou, et al.. (2023). Non-Alcoholic Fatty Liver Disease and Echocardiographic Parameters of Left Ventricular Diastolic Function: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences. 24(18). 14292–14292. 9 indexed citations
6.
Nasiri‐Ansari, Narjes, et al.. (2023). The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review. European Journal of Clinical Pharmacology. 80(1). 127–150. 18 indexed citations
7.
Tsave, O., Antonios G. Hatzidimitriou, Maria P. Yavropoulou, et al.. (2023). Structural Speciation of Ti(IV)-(α-Hydroxycarboxylic Acid) Complexes in Metabolism-Related (Patho)Physiology—In Vitro Approaches to (Pre)Adipocyte Differentiation and Mineralization. International Journal of Molecular Sciences. 24(14). 11865–11865. 3 indexed citations
8.
Yavropoulou, Maria P., et al.. (2022). Management and Long-Term Follow-Up of Hyperparathyroidism in Multiple Endocrine Neoplasia Type 1: Single Center Experience. Journal of Clinical Medicine. 11(7). 1967–1967. 7 indexed citations
9.
Flessa, Christina‐Maria, Narjes Nasiri‐Ansari, Ioannis Kyrou, et al.. (2022). Genetic and Diet-Induced Animal Models for Non-Alcoholic Fatty Liver Disease (NAFLD) Research. International Journal of Molecular Sciences. 23(24). 15791–15791. 64 indexed citations
10.
Nasiri‐Ansari, Narjes, Eliana Spilioti, Ioannis Kyrou, et al.. (2022). Estrogen Receptor Subtypes Elicit a Distinct Gene Expression Profile of Endothelial-Derived Factors Implicated in Atherosclerotic Plaque Vulnerability. International Journal of Molecular Sciences. 23(18). 10960–10960. 8 indexed citations
11.
Banos, Aggelos, Aikaterini Hatzioannou, Andreas Kloetgen, et al.. (2021). Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors. Cancer Immunology Research. 9(7). 726–734. 30 indexed citations
12.
Angelousi, Anna, et al.. (2021). Diabetes insipidus secondary to sellar/parasellar lesions. Journal of Neuroendocrinology. 33(3). e12954–e12954. 11 indexed citations
13.
Zografos, George, Eva Kassi, Georgios Kyriakopoulos, et al.. (2021). Adrenocortical Cancer: A 20-Year Experience of a Single Referral Center in Prognosis and Outcomes. Hormone and Metabolic Research. 53(11). 709–716. 2 indexed citations
14.
Nasiri‐Ansari, Narjes, Ioannis Kyrou, Christos S. Mantzoros, et al.. (2021). Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis. International Journal of Molecular Sciences. 22(2). 818–818. 234 indexed citations breakdown →
15.
Mallis, Panagiotis, Michalis Katsimpoulas, Alkiviadis Kostakis, et al.. (2020). Vitrified Human Umbilical Arteries as Potential Grafts for Vascular Tissue Engineering. Tissue Engineering and Regenerative Medicine. 17(3). 285–299. 23 indexed citations
16.
Tsoli, Marina, Gregory Kaltsas, Anna Angelousi, et al.. (2020). Managing Ipilimumab-Induced Hypophysitis: Challenges and Current Therapeutic Strategies. SHILAP Revista de lepidopterología. 1 indexed citations
17.
Nasiri‐Ansari, Narjes, Georgios K. Dimitriadis, Gerasimos Siasos, et al.. (2019). Orexin-A Exerts Equivocal Role in Atherosclerosis Process Depending on the Duration of Exposure: In Vitro Study. Nutrients. 12(1). 53–53. 3 indexed citations
18.
Dimitriadis, Georgios K., Narjes Nasiri‐Ansari, Georgios Agrogiannis, et al.. (2019). Empagliflozin improves primary haemodynamic parameters and attenuates the development of atherosclerosis in high fat diet fed APOE knockout mice. Molecular and Cellular Endocrinology. 494. 110487–110487. 43 indexed citations
19.
Kassi, Eva, Anna Angelousi, Panagiotis Diamantopoulos, et al.. (2019). Endocrine‐related adverse events associated with immune‐checkpoint inhibitors in patients with melanoma. Cancer Medicine. 8(15). 6585–6594. 43 indexed citations
20.
Angelousi, Anna, et al.. (2016). Expression of sodium iodide symporter in human breast tissues.. PubMed. 21(1). 53–60. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Choon Hee Chung Breakdown of academic impact, for papers by Sidney Tam Breakdown of academic impact, for papers by Naoto Nakamura Breakdown of academic impact, for papers by Bogusław Okopień Breakdown of academic impact, for papers by Giovanni Tarantino Breakdown of academic impact, for papers by Massimo Collino Breakdown of academic impact, for papers by Carla Lubrano Breakdown of academic impact, for papers by Guang Ning Breakdown of academic impact, for papers by Goji Hasegawa Breakdown of academic impact, for papers by Carlo Sabbà
Rankless by CCL
2026